Ulrich Sachs: A New Strategy to Prevent Platelet Transfusion Refractoriness
Ulrich Sachs, Chief Physician at University Hospital Giessen and Marburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in The Journal of Immunology, adding:
“I am delighted that we are part of this fruitful cooperation with the team of Alan Lazarus in Toronto, Canada.
A monovalent single-chain variable fragment antibody that targets the human Fc gamma receptor IIIA prevents destructive platelet phagocytosis in a humanized mouse model of platelet transfusion refractoriness.
That‘s excellent news! And it offers hope of a simple solution to a major everyday problem in transfusion medicine: providing platelet transfusions to patients with antibodies against HLA.”
Title: FcγRIII blockade prevents anti-HLA–mediated platelet clearance in a humanized murine model of platelet transfusion refractoriness
Authors: Lazaro Gil Gonzalez, Kevin Doyoon Won, Zoya Tawhidi, Alequis Pavon Oro, Yaima Tundidor Cabado, Yoelys Cruz-Leal, Akash Gupta, Hanna Wabnitz, Ulrich J. Sachs, Rick Kapur, Alan H. Lazarus

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 1, 2026, 11:07Yashaswi Dhiman: Advancing Hemovigilance Through Award-Winning Science
-
Aug 1, 2026, 08:24Kayla Garrett: Transforming Expectations in Haemophilia A Care
-
Aug 1, 2026, 07:51Toyosi Onwuemene: Are We Measuring the Outcomes That Matter Most to Patients With TTP?
-
Aug 1, 2026, 07:51Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?
-
Aug 1, 2026, 07:38Danny Hsu: Recognizing Excellence in Scientific Leadership at ISTH 2026
-
Aug 1, 2026, 07:12Gijs Aertssen: New Evidence on Joint Prosthesis Survival in Inherited Bleeding Disorders
-
Aug 1, 2026, 06:58Nora Abazi Emini: New Insights into Factor XIII in Atypical Haemolytic Uraemic Syndrome
-
Aug 1, 2026, 06:30Understanding Natural Anticoagulant Deficiencies – JTH
-
Aug 1, 2026, 06:26Fiona Robinson: Webinar – What’s New in Hemophilia A Research?